Dr Fuchs will replace longtime BioMarin chief medical officer, Emil Kakkis. Dr Fuchs most recently served as executive vice president and chief medical officer of Onyx Pharmaceuticals.
Dr Fuchs has received an MD degree from George Washington University and a BA degree in biochemical sciences from Harvard University.
Jean-Jacques Bienaime, CEO of BioMarin, said: “We are extremely pleased to welcome Dr Henry Fuchs to BioMarin. He is uniquely qualified to fill this important role in the company. As an experienced CMO and CEO, he has demonstrated a strength of vision and execution from the laboratory to the marketplace and will be a highly capable contributor to our ongoing scientific and business development efforts.”